Ceftazidime Injection
- Brand(s)
- Fortaz, Tazicef
- Category(s)
- prescription
- SPL Type(s)
- Human Prescription
- Master SPL
- Covis Pharmaceuticals, Inc. (2014-10-08)
- Oldest Current Product
- 1986-03-06
- License(s)
- NDA, ANDA
- RxNORM
- INJECTION\CEFTAZIDIME
- FDAOB
- INJECTION\INJECTION\CEFTAZIDIME SODIUM\rdfq
INJECTION\INJECTION\CEFTAZIDIME\rdfq - SPL Active
- INTRAMUSCULAR\INJECTION, POWDER, FOR SOLUTION\CEFTAZIDIME
INTRAMUSCULAR\INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION\CEFTAZIDIME SODIUM
INTRAVENOUS\INJECTION, POWDER, FOR SOLUTION\CEFTAZIDIME
INTRAVENOUS\INJECTION, SOLUTION\CEFTAZIDIME - SPL Moiety
- INTRAMUSCULAR\INJECTION, POWDER, FOR SOLUTION\CEFTAZIDIME ANHYDROUS
INTRAMUSCULAR\INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION\CEFTAZIDIME
INTRAVENOUS\INJECTION, POWDER, FOR SOLUTION\CEFTAZIDIME ANHYDROUS
INTRAVENOUS\INJECTION, SOLUTION\CEFTAZIDIME ANHYDROUS
product(s) by strength(s)
ceftazidime 1000 mg injection
original product(s)(s)
# | id | brand | category | labeler | first marketed | active ingredient(s) | route | dose form | application | spl |
---|---|---|---|---|---|---|---|---|---|---|
1 | 002643143 | NDA | B. Braun Medical Inc. | 2011-06-13 | CEFTAZIDIME | INTRAVENOUS | INJECTION, SOLUTION | NDA050823 | 1b41f272-0727-4ce5-a4af-6255061a08b0 | |
2 | 249870378 | Fortaz | NDA | Covis Pharmaceuticals, Inc. | 2012-12-14 | CEFTAZIDIME | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | NDA050578 | 981b9abe-4c76-41b2-8f36-eb3e28fa5adc |
3 | 249870412 | Fortaz | NDA | Covis Pharmaceuticals, Inc. | 2013-04-15 | CEFTAZIDIME | INTRAVENOUS | INJECTION, SOLUTION | NDA050634 | 981b9abe-4c76-41b2-8f36-eb3e28fa5adc |
generic product(s)(s)
# | id | brand | category | labeler | first marketed | active ingredient(s) | route | dose form | application | spl |
---|---|---|---|---|---|---|---|---|---|---|
1 | 004095082 | Tazicef | ANDA | Hospira, Inc. | 1986-03-06 | CEFTAZIDIME | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | ANDA062662 | 40d48c5d-650e-461b-a67b-7e65772d1b92 |
2 | 004095092 | Tazicef | ANDA | Hospira, Inc. | 1993-10-31 | CEFTAZIDIME | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | ANDA064032 | 9b73979c-c95a-4433-0a9d-f9cea3cb557f |
3 | 250210127 | ANDA | Sagent Pharmaceuticals | 2008-05-15, 2015-07-01 | CEFTAZIDIME | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | ANDA062640 | 112c5457-8d71-49f5-b531-9761d7d38c93, bfd92fd8-3014-44dd-b69b-4276262a51fa | |
4 | 445670235 | ANDA | Wg Critical Care, Llc | 2013-01-31 | CEFTAZIDIME | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | ANDA062640 | bcc81df2-20e3-4738-bfcf-301da883c1d9 |
relabeler product(s)(s)
# | id | brand | category | labeler | first marketed | active ingredient(s) | route | dose form | equivalent product | application | spl |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 551541125 | Fortaz | NDA | Cardinal Health | 1992-08-26 | CEFTAZIDIME SODIUM | INTRAMUSCULAR | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 001730434 | NDA050578 | fd2fa2af-5929-4152-afd3-55e4e162f765 |
ceftazidime 2000 mg injection
original product(s)(s)
# | id | brand | category | labeler | first marketed | active ingredient(s) | route | dose form | application | spl |
---|---|---|---|---|---|---|---|---|---|---|
1 | 002643145 | NDA | B. Braun Medical Inc. | 2011-06-13 | CEFTAZIDIME | INTRAVENOUS | INJECTION, SOLUTION | NDA050823 | 1b41f272-0727-4ce5-a4af-6255061a08b0 | |
2 | 249870379 | Fortaz | NDA | Covis Pharmaceuticals, Inc. | 2012-12-14 | CEFTAZIDIME | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | NDA050578 | 981b9abe-4c76-41b2-8f36-eb3e28fa5adc |
3 | 249870413 | Fortaz | NDA | Covis Pharmaceuticals, Inc. | 2013-04-15 | CEFTAZIDIME | INTRAVENOUS | INJECTION, SOLUTION | NDA050634 | 981b9abe-4c76-41b2-8f36-eb3e28fa5adc |
generic product(s)(s)
# | id | brand | category | labeler | first marketed | active ingredient(s) | route | dose form | application | spl |
---|---|---|---|---|---|---|---|---|---|---|
1 | 004095084 | Tazicef | ANDA | Hospira, Inc. | 1986-03-06 | CEFTAZIDIME | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | ANDA062662 | 40d48c5d-650e-461b-a67b-7e65772d1b92 |
2 | 004095093 | Tazicef | ANDA | Hospira, Inc. | 1993-10-31 | CEFTAZIDIME | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | ANDA064032 | 9b73979c-c95a-4433-0a9d-f9cea3cb557f |
3 | 250210128 | ANDA | Sagent Pharmaceuticals | 2008-05-15, 2015-07-01 | CEFTAZIDIME | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | ANDA062640 | 112c5457-8d71-49f5-b531-9761d7d38c93, bfd92fd8-3014-44dd-b69b-4276262a51fa | |
4 | 445670236 | ANDA | Wg Critical Care, Llc | 2013-01-31 | CEFTAZIDIME | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | ANDA062640 | bcc81df2-20e3-4738-bfcf-301da883c1d9 |
ceftazidime 500 mg injection
original product(s)(s)
# | id | brand | category | labeler | first marketed | active ingredient(s) | route | dose form | application | spl |
---|---|---|---|---|---|---|---|---|---|---|
1 | 249870377 | Fortaz | NDA | Covis Pharmaceuticals, Inc. | 2012-12-14 | CEFTAZIDIME | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | NDA050578 | 981b9abe-4c76-41b2-8f36-eb3e28fa5adc |
application(s)
application drug(s)
# | id | category/deprecated | ingredient strength(s) | dose form | rld | TE | approved | application |
---|---|---|---|---|---|---|---|---|
1 | ANDA062640_001 | RX | CEFTAZIDIME (500MG/VIAL) | INJECTION | False | AP | 1985-11-20 | CEFTAZIDIME |
2 | ANDA062640_002 | RX | CEFTAZIDIME (1GM/VIAL) | INJECTION | False | AP | 1985-11-20 | CEFTAZIDIME |
3 | ANDA062640_003 | RX | CEFTAZIDIME (2GM/VIAL) | INJECTION | False | AP | 1985-11-20 | CEFTAZIDIME |
4 | ANDA062640_004 | RX | CEFTAZIDIME (6GM/VIAL) | INJECTION | False | AP | 1992-02-03 | CEFTAZIDIME |
5 | ANDA062655_001 | discontinued | CEFTAZIDIME (1GM/VIAL) | INJECTION | False | 1985-11-20 | TAZIDIME | |
6 | ANDA062655_002 | discontinued | CEFTAZIDIME (2GM/VIAL) | INJECTION | False | 1985-11-20 | TAZIDIME | |
7 | ANDA062662_001 | RX | CEFTAZIDIME (500MG/VIAL) | INJECTION | False | AP | 1986-03-06 | TAZICEF |
8 | ANDA062662_002 | RX | CEFTAZIDIME (1GM/VIAL) | INJECTION | False | AP | 1986-03-06 | TAZICEF |
9 | ANDA062662_003 | RX | CEFTAZIDIME (2GM/VIAL) | INJECTION | False | AP | 1986-03-06 | TAZICEF |
10 | ANDA062662_004 | RX | CEFTAZIDIME (6GM/VIAL) | INJECTION | False | AP | 1986-03-06 | TAZICEF |
11 | ANDA062739_001 | discontinued | CEFTAZIDIME (1GM/VIAL) | INJECTION | False | 1986-07-10 | TAZIDIME IN PLASTIC CONTAINER | |
12 | ANDA062739_002 | discontinued | CEFTAZIDIME (2GM/VIAL) | INJECTION | False | 1986-07-10 | TAZIDIME IN PLASTIC CONTAINER | |
13 | ANDA063221_001 | discontinued | CEFTAZIDIME SODIUM (EQ 10MG BASE/ML) | INJECTION | False | 1993-04-29 | CEFTAZIDIME SODIUM IN PLASTIC CONTAINER | |
14 | ANDA063221_002 | discontinued | CEFTAZIDIME SODIUM (EQ 20MG BASE/ML) | INJECTION | False | 1993-04-29 | CEFTAZIDIME SODIUM IN PLASTIC CONTAINER | |
15 | ANDA063221_003 | discontinued | CEFTAZIDIME SODIUM (EQ 40MG BASE/ML) | INJECTION | False | 1993-04-29 | CEFTAZIDIME SODIUM IN PLASTIC CONTAINER | |
16 | ANDA063322_001 | discontinued | CEFTAZIDIME (1GM/VIAL) | INJECTION | False | 1995-11-07 | PENTACEF | |
17 | ANDA063322_002 | discontinued | CEFTAZIDIME (2GM/VIAL) | INJECTION | False | 1995-11-07 | PENTACEF | |
18 | ANDA064006_001 | discontinued | CEFTAZIDIME (1GM/VIAL) | INJECTION | False | 1992-03-31 | PENTACEF | |
19 | ANDA064006_002 | discontinued | CEFTAZIDIME (2GM/VIAL) | INJECTION | False | 1992-03-31 | PENTACEF | |
20 | ANDA064008_001 | discontinued | CEFTAZIDIME (6GM/VIAL) | INJECTION | False | 1992-03-31 | PENTACEF | |
21 | ANDA064008_002 | discontinued | CEFTAZIDIME (10GM/VIAL) | INJECTION | False | 1992-03-31 | PENTACEF | |
22 | ANDA064032_001 | RX | CEFTAZIDIME (1GM/VIAL) | INJECTION | False | AP | 1993-10-31 | TAZICEF |
23 | ANDA064032_002 | RX | CEFTAZIDIME (2GM/VIAL) | INJECTION | False | AP | 1993-10-31 | TAZICEF |
24 | ANDA065196_001 | RX | CEFTAZIDIME (1GM/VIAL) | INJECTION | False | AP | 2008-10-15 | CEFTAZIDIME |
25 | ANDA065481_001 | discontinued | CEFTAZIDIME (500MG/VIAL) | INJECTION | False | 2010-05-28 | CEFTAZIDIME | |
26 | ANDA065481_002 | discontinued | CEFTAZIDIME (1GM/VIAL) | INJECTION | False | 2010-05-28 | CEFTAZIDIME | |
27 | ANDA065481_003 | discontinued | CEFTAZIDIME (2GM/VIAL) | INJECTION | False | 2010-05-28 | CEFTAZIDIME | |
28 | ANDA065482_001 | discontinued | CEFTAZIDIME (6GM/VIAL) | INJECTION | False | 2010-05-28 | CEFTAZIDIME | |
29 | NDA050578_001 | RX | CEFTAZIDIME (500MG/VIAL) | INJECTION | True | AP | 1985-07-19 | FORTAZ |
30 | NDA050578_002 | RX | CEFTAZIDIME (1GM/VIAL) | INJECTION | True | AP | 1985-07-19 | FORTAZ |
31 | NDA050578_003 | RX | CEFTAZIDIME (2GM/VIAL) | INJECTION | True | AP | 1985-07-19 | FORTAZ |
32 | NDA050578_004 | RX | CEFTAZIDIME (6GM/VIAL) | INJECTION | True | AP | 1985-07-19 | FORTAZ |
33 | NDA050634_001 | discontinued | CEFTAZIDIME SODIUM (EQ 10MG BASE/ML) | INJECTION | False | 1989-04-28 | FORTAZ IN PLASTIC CONTAINER | |
34 | NDA050634_002 | RX | CEFTAZIDIME SODIUM (EQ 20MG BASE/ML) | INJECTION | True | 1989-04-28 | FORTAZ IN PLASTIC CONTAINER | |
35 | NDA050634_003 | RX | CEFTAZIDIME SODIUM (EQ 40MG BASE/ML) | INJECTION | True | 1989-04-28 | FORTAZ IN PLASTIC CONTAINER | |
36 | NDA050646_001 | discontinued | CEFTAZIDIME (500MG/VIAL) | INJECTION | False | 1990-09-27 | CEPTAZ | |
37 | NDA050646_002 | discontinued | CEFTAZIDIME (1GM/VIAL) | INJECTION | False | 1990-09-27 | CEPTAZ | |
38 | NDA050646_003 | discontinued | CEFTAZIDIME (2GM/VIAL) | INJECTION | False | 1990-09-27 | CEPTAZ | |
39 | NDA050646_004 | discontinued | CEFTAZIDIME (10GM/VIAL) | INJECTION | False | 1990-09-27 | CEPTAZ | |
40 | NDA050823_001 | RX | CEFTAZIDIME (EQ 1GM BASE) | INJECTION | False | 2011-06-13 | CEFTAZIDIME IN DEXTROSE CONTAINER | |
41 | NDA050823_002 | RX | CEFTAZIDIME (EQ 2GM BASE) | INJECTION | True | 2011-06-13 | CEFTAZIDIME IN DEXTROSE CONTAINER |
spl(s)
# | id | title | category | type | labeler | labeler act | last update | version | product(s) | in other drug docs |
---|---|---|---|---|---|---|---|---|---|---|
1 | 112c5457-8d71-49f5-b531-9761d7d38c93 (view SPL) | Ceftazidime for Injection, USP | prescription | Human Prescription | Sagent Pharmaceuticals | 2015-01-08 | 6 | 250210127, 250210128 | ||
2 | 1b41f272-0727-4ce5-a4af-6255061a08b0 (view SPL) | These highlights do not include all the information needed to use CEFTAZIDIME for Injection USP and DEXTROSE Injection USP safely and effectively. See full prescribing information for CEFTAZIDIME for Injection USP and DEXTROSE Injection USP. C EFTAZIDIME for injection USP and DEXTROSE injection USP, for intravenous use Initial U.S. Approval: 1985 | prescription | Human Prescription | B. Braun Medical Inc. | 2015-05-29 | 11 | 002643143, 002643145 | ||
3 | 40d48c5d-650e-461b-a67b-7e65772d1b92 (view SPL) | PRESCRIBING INFORMATIONRx only TAZICEF brand of ceftazidime for injection, USP | prescription | Human Prescription | Hospira, Inc. | 2014-10-27 | 2 | 004095082, 004095084 | ||
4 | 757c31dc-99ef-4960-b118-738b79631b1a (view SPL) | Ceftazidime for Injection, USP | prescription | Human Prescription | Sandoz Inc | 2015-07-27 | 12 | 007813177, 007813178 | ||
5 | 981b9abe-4c76-41b2-8f36-eb3e28fa5adc (view SPL) | FORTAZ (ceftazidime for injection)FORTAZ (ceftazidime injection) | prescription | Human Prescription | Covis Pharmaceuticals, Inc. | MANUFACTURE, PACK | 2014-10-08 | 5 | 249870377, 249870378, 249870379, 249870412, 249870413, 249870382, 249870434, 249870435 | Ceftazidime Injectable Solution |
6 | 9b73979c-c95a-4433-0a9d-f9cea3cb557f (view SPL) | PRESCRIBING INFORMATIONTAZICEF Rx only | prescription | Human Prescription | Hospira, Inc. | 2014-10-27 | 14 | 004095092, 004095093 | ||
7 | bcc81df2-20e3-4738-bfcf-301da883c1d9 (view SPL) | Ceftazidime for Injection | prescription | Human Prescription | Wg Critical Care, Llc | 2015-01-22 | 2 | 445670235, 445670236 | ||
8 | bfd92fd8-3014-44dd-b69b-4276262a51fa (view SPL) | Ceftazidime for Injection, USPFor Intravenous or Intramuscular Use | prescription | Human Prescription | Sagent Pharmaceuticals | 2015-03-13 | 2 | 250210127, 250210128 | ||
9 | fd2fa2af-5929-4152-afd3-55e4e162f765 (view SPL) | FORTAZ (ceftazidime for injection)FORTAZ (ceftazidime injection) | prescription | Human Prescription | Cardinal Health | REPACK | 2011-06-13 | 1 | 551541125 |
Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII